The Wall Street Journal
SAN ANTONIO, Texas -- New findings suggest that the risks associated with a class of chemotherapy drugs widely used to treat breast cancer outweighed their benefits in some patients.
findings, presented at the San Antonio Breast Cancer Symposium on
Saturday, renewed a debate over whether the chemotherapy drugs
anthracyclines, which have been around since the 1960s, should remain
the standard of care in treating breast cancer, or whether newer drugs
should be used more frequently instead... Read More